RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been assigned an average rating of “Hold” from the six analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $3.00.

RAPT has been the subject of a number of analyst reports. UBS Group reduced their price objective on RAPT Therapeutics from $2.00 to $1.00 and set a “neutral” rating for the company in a research report on Thursday, May 22nd. HC Wainwright upgraded RAPT Therapeutics to a “strong-buy” rating and set a $6.00 price objective for the company in a research report on Thursday, May 22nd. Finally, Wall Street Zen upgraded RAPT Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd.

Institutional Trading of RAPT Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its stake in RAPT Therapeutics by 401.9% during the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after acquiring an additional 42,636 shares in the last quarter. Sei Investments Co. bought a new stake in shares of RAPT Therapeutics in the 4th quarter worth $64,000. Nuveen Asset Management LLC raised its stake in shares of RAPT Therapeutics by 50.5% in the 4th quarter. Nuveen Asset Management LLC now owns 116,925 shares of the company’s stock worth $185,000 after buying an additional 39,216 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of RAPT Therapeutics by 1,128.3% in the 4th quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company’s stock worth $324,000 after buying an additional 188,461 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of RAPT Therapeutics by 25.5% in the 4th quarter. Renaissance Technologies LLC now owns 369,736 shares of the company’s stock worth $584,000 after buying an additional 75,136 shares in the last quarter. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Trading Up 2.6%

Shares of RAPT opened at $1.20 on Tuesday. The firm has a market cap of $158.75 million, a price-to-earnings ratio of -0.43 and a beta of -0.11. The stock has a 50 day moving average of $0.92 and a 200-day moving average of $1.12. RAPT Therapeutics has a 52 week low of $0.71 and a 52 week high of $3.99.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.23. On average, sell-side analysts predict that RAPT Therapeutics will post -2.14 earnings per share for the current fiscal year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.